Inhibition of IGF-1R-dependent PI3K activation sensitizes colon cancer cells specifically to DR5-mediated apoptosis but not to rhTRAIL
- PMID: 21538027
- DOI: 10.1007/s13402-011-0033-9
Inhibition of IGF-1R-dependent PI3K activation sensitizes colon cancer cells specifically to DR5-mediated apoptosis but not to rhTRAIL
Abstract
Background: Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) initiates apoptosis in tumor cells upon binding to its cognate agonistic receptors, death receptors 4 and 5 (DR4 and DR5). The activity of the insulin-like growth factor 1 (IGF-1) survival pathway is often increased in cancer, influencing both cell proliferation and apoptosis. We hypothesized that inhibiting the IGF-1 receptor (IGF-1R) using NVP-AEW541, a small molecular weight tyrosine kinase inhibitor of the IGF-1R, could increase death receptor (DR)-mediated apoptosis in colon cancer cells.
Methods: The analyses were performed by caspase assay, flow cytometry, Western blotting, immunoprecipitation and fluorescent microscopy.
Results: Preincubation with NVP-AEW541 surprisingly decreased apoptosis induced by recombinant human TRAIL (rhTRAIL) or an agonistic DR4 antibody while sensitivity to an agonistic DR5 antibody was increased. NVP-AEW541 could inhibit IGF-1-induced activation of the phosphatidylinositol 3-kinase (PI3K) pathway. The effects of the PI3K inhibitor LY294002 on TRAIL-induced apoptosis were similar to those of NVP-AEW541, further supporting a role for IGF-1R-mediated activation of PI3K. We show that PI3K inhibition enhances DR5-mediated caspase 8 processing but also lowers DR4 membrane expression and DR4-mediated caspase 8 processing. Inhibition of PI3K reduced rhTRAIL sensitivity independently of the cell line preference for either DR4- or DR5-mediated apoptosis signaling.
Conclusions: Our study indicates that individual effects on DR4 and DR5 apoptosis signaling should be taken into consideration when combining DR-ligands with PI3K inhibition.
Similar articles
-
Inhibition of IGF-1R-dependent PI3K activation sensitizes colon cancer cells specifically to DR5-mediated apoptosis but not to rhTRAIL.Anal Cell Pathol (Amst). 2010;33(5):229-44. doi: 10.3233/ACP-CLO-2010-0549. Anal Cell Pathol (Amst). 2010. PMID: 20978316 Free PMC article.
-
Modulation of TRAIL resistance in colon carcinoma cells: different contributions of DR4 and DR5.BMC Cancer. 2011 Jan 27;11:39. doi: 10.1186/1471-2407-11-39. BMC Cancer. 2011. PMID: 21272366 Free PMC article.
-
Targeting pro-apoptotic trail receptors sensitizes HeLa cervical cancer cells to irradiation-induced apoptosis.Int J Radiat Oncol Biol Phys. 2008 Oct 1;72(2):543-52. doi: 10.1016/j.ijrobp.2008.06.1902. Int J Radiat Oncol Biol Phys. 2008. PMID: 18793956
-
Intracellular localization of DR5 and related regulatory pathways as a mechanism of resistance to TRAIL in cancer.Cell Mol Life Sci. 2017 Jan;74(2):245-255. doi: 10.1007/s00018-016-2321-z. Epub 2016 Aug 10. Cell Mol Life Sci. 2017. PMID: 27510421 Free PMC article. Review.
-
Something old, something new and something borrowed: emerging paradigm of insulin-like growth factor type 1 receptor (IGF-1R) signaling regulation.Cell Mol Life Sci. 2014 Jul;71(13):2403-27. doi: 10.1007/s00018-013-1514-y. Epub 2013 Nov 26. Cell Mol Life Sci. 2014. PMID: 24276851 Free PMC article. Review.
Cited by
-
A virtual screen identified C96 as a novel inhibitor of phosphatidylinositol 3-kinase that displays potent preclinical activity against multiple myeloma in vitro and in vivo.Oncotarget. 2014 Jun 15;5(11):3836-48. doi: 10.18632/oncotarget.1657. Oncotarget. 2014. PMID: 25003534 Free PMC article.
-
Subcutaneous administration of rhIGF-I post irradiation exposure enhances hematopoietic recovery and survival in BALB/c mice.J Radiat Res. 2012 Jul;53(4):581-7. doi: 10.1093/jrr/rrs029. Epub 2012 Jun 14. J Radiat Res. 2012. PMID: 22843623 Free PMC article.
-
Anticancer activity of the type I insulin-like growth factor receptor antagonist, ganitumab, in combination with the death receptor 5 agonist, conatumumab.Target Oncol. 2015 Mar;10(1):65-76. doi: 10.1007/s11523-014-0315-z. Epub 2014 May 11. Target Oncol. 2015. PMID: 24816908 Free PMC article. Clinical Trial.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous